In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

NACIAM: N-acetylcysteine Offers a Post-MI Boost

Myocardial Disease
Cardiovascular Surgery
Invasive and Interventional Cardiology, Cardiovascular Surgery


Rome, Italy – 28 August 2016: The addition of intravenous (IV) N-acetylcysteine (NAC) to IV glyceryl trinitrate (GTN) significantly reduced infarct size by approximately one third in patients undergoing percutaneous coronary intervention (PCI) after ST-segment elevation acute myocardial infarction (STEMI), according to Hot Line research reported here.

“Timely and effective myocardial reperfusion by PCI is the treatment of choice for limiting myocardial infarct size and improving clinical outcomes in patients presenting with STEMI. However, additional pharmacological interventions may help to reduce infarct size further,” noted Sivabaskari Pasupathy, PhD candidate, from the University of Adelaide, in Adelaide, Australia, who presented the findings at ESC Congress 2016.

“Any intervention that actually reduces myocardial infarct size by approximately a third might reasonably be expected to substantially improve long-term outcomes.”

NACIAM (N-AcetylCysteine In Acute Myocardial infarction), a placebo-controlled, double-blind trial, included 112 STEMI patients (mean age 64 years) from 3 Australian hospitals.

All patients underwent emergency PCI and also received low dose intravenous GTN. They were randomized pre-PCI to receive either high dose (15 grams/24 hours) NAC or an identical placebo, both delivered intravenously over 48 hours, “with the hypothesis that NAC might reduce infarct size, either by potentiating the effects of GTN or via ‘scavenging’ of reactive oxygen species,” said Dr. Pasupathy.

Cardiac magnetic resonance (CMR) imaging performed within one week (early) and again 3 months post MI (late) showed that patients who received NAC had reductions in infarct size of 33% and 50% respectively compared to placebo (p=0.02 for both).

There was a similar but not significant trend towards reduction in creatine kinase release.

Additionally, myocardial salvage, measured at one week, was approximately doubled in patients who received NAC (60% vs 27%, p<0.001), and there was also evidence of accelerated tissue reperfusion and hypochlorous acid “scavenging” in these patients.

Over 2 years of follow-up, the combination of cardiac readmissions and deaths was less frequent in NAC-treated (3 vs 16 patients, P<0.01).

Safety endpoints including hypotension, bleeding, and contrast-induced nephropathy were similar in both groups.

“Intravenous NAC administration was associated with more rapid chest pain resolution, improved myocardial salvage, a favourable in-hospital safety profile, sustained infarct size reduction at 3 months post-STEMI, and promising clinical outcomes at 2 years,” concluded Dr. Pasupathy. “While the results of this study are encouraging, we would prefer to regard NACIAM as the precursor of a follow-up study, sized for clinical end-points,” she noted.

Ends

 

Notes to editor

Sources of funding: Supported by a grant-in-aid from Australian National Heart Foundation.

Disclosures: None

ESC Press Office
For background information, please contact the ESC Press Office.

For press enquiries, please contact, the Media & Press Coordinator, Jacques Olivier Costa: +393427028575 

For independent comment on site, please contact the ESC Spokesperson coordinator, Celine Colas: +393402405148 

The press conference timetable is available here. 

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 120 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2016

ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2016 takes place 27 to 31 August at the Fiera di Roma in Rome, Italy. The scientific programme is here. More information is available from the ESC Press Office at press@escardio.org

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2016. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.